JUL 13, 2018 01:49 PM PDT

Pharmacological Strategy Attempts To Treat Multiple Symptoms of Fragile X

WRITTEN BY: Nouran Amin

Recent research in a mouse model of fragile X syndrome (FXS), scheduled for publication in Neuropsychopharmacology, shows that a pharmacological strategy can reduce multiple behavioral and cellular deficiencies in the most common inherited form of intellectual disability and a major single-gene cause of autism spectrum disorders.

When a compound, by the name GSK6A, was given to mice lacking the Fmr1 gene, an established animal model of fragile X syndrome, symptomatic behaviors were alleviated including impaired social interactions and decision making, displayed by individuals with fragile X syndrome.

Results showed that treatment with GSK6A, an inhibitor of a cellular signaling enzyme called p110β form of PI3 (phosphoinositide-3) kinase, may serve as a logical strategy for treating cognitive and behavioral problems in fragile X syndrome; the efficacy, of course, would be evaluated in human clinical trials.

"Our results suggest that p110β inhibitors can be repurposed for fragile X syndrome, and they have implications for other subtypes of autism spectrum disorders that are characterized by similar alterations of this pathway," says Gary Bassell, Ph.D., professor and chair of cell biology at Emory University School of Medicine. "Right now, no proven effective treatments are available for fragile X syndrome that are targeted to the disease mechanism," Gross says. "We think that p110β is an appropriate target because it is directly regulated by FMRP, and it is overactivated in both mouse models and patient cell lines."

To ensure that undesirable side-effects of the pharmacological strategy do not appear, the researchers are first planning long-term animal studies on p110β inhibitors in fragile X syndrome.

1 in 3000 males and 1 in 6000 females are affected with Fragile X and females often have milder symptoms. Affected children may display intellectual disability with a delay of milestones such as speech. They may also feature autism-like features including impaired social skills, gaze aversion/social anxiety, hyperactivity and repetitive behaviors.

FXS is a result the silencing of a single gene, FMR1, which prevents the production of an RNA binding protein known as FMRP. FMRP manages the production of several proteins at synapses, the sites of communication between neurons.

In the current study, short-term treatments are only considered which covers one or two injections. For one experiment, mice were treated for 10 days, which normalized their densities of dendritic spines present in the hippocampus. Synaptic structures are overabundant in the absence of FMRP in animals and humans with FXS.

"It is likely that PI3 kinase—in its various forms—needs to be kept in a tight balance at the synapse," Bassell says. "Too much or too little can tip things into a suboptimal zone, especially for complex behaviors. We think targeting the excess p110β in FXS can restore signaling between upstream and downstream defects linked to the absence of FMRP. We can't use mouse behavioral tests alone to understand a drug's effects," Bassell says. "It is critical to have molecular, cellular and neurophysiological phenotypes, which we and others do."

Source: Journal of Neuropsychopharmacology, Science Daily, Medical Xpress

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 15, 2019
Drug Discovery
SEP 15, 2019
Tart Cherry and Pain Management in Breast Cancer Patients
In patients with non-metastatic breast cancer, treated with aromatase inhibitors, tart cherry was found to reduce the musculoskeletal effects of the drug. ...
SEP 15, 2019
Cell & Molecular Biology
SEP 15, 2019
Scientists Discover Why Arteries Harden & Find a Potential Treatment
As we get older, our arteries slowly begin to stiffen and then harden, which can lead to many serious complications. Now there may be a way to treat it....
SEP 15, 2019
Health & Medicine
SEP 15, 2019
Remember Joe Camel? E-cigarette cartoon ads increase the chances of vaping
Do you remember the infamous "Joe Camel" advertisements for cigarettes back in the 1980s and 90s? These ads successfully got a generation of youn...
SEP 15, 2019
Drug Discovery
SEP 15, 2019
Drug Delays Type 1 Diabetes in High Risk Individuals
An immunotherapeutic, involving anti-CD3 monoclonal antibody (teplizumab), was seen to slow down the progression to clinical type 1 diabetes in high risk i...
SEP 15, 2019
Drug Discovery
SEP 15, 2019
Remote Controlled Drug Delivery?
According to the CDC, chronic diseases although the most common are preventable of all medical problems. Chronic diseases ranging from arthritis to heart d...
SEP 15, 2019
Drug Discovery
SEP 15, 2019
Drug Reduces Heart Attacks in Diabetic Patients
Recent results from a clinical trial that evaluated the addition of a drug called ‘ticagrelor’ to aspirin were shown to improve clinical outcom...
Loading Comments...